eMAX Health EMRClaims+ (USA)

Field Names
Records
Coordinating Country
United States
Region
United States

(Midwestern and Northeast USA)

Brief Database Description

EMRClaims+ database is a proprietary database managed by eMAX Health. The database integrates EMR details with longitudinal claims for complete patient follow-up including lab results. The EMRClaims+ database is derived through contracted payer, provider, and specialty pharmacy networks in order to provide comprehensive data on healthcare service and all aspects of clinical care for >20 million patients treated across 9 states of the United States from Midwest to the Northeast since 1988. Data from Northeastern USA were added to the database in 2016, although the information contained in the Northeast component goes back to 2000. The Northeast component of the data includes de-identified, EMR based data extracts from care provided to more than 2 million residents throughout northeast US representing both inpatient and outpatient settings, as well as medical, hospital and pharmacy claims.

The database accesses administrative insurance claims and links that to an overlapping provider database of electronic medical records (EMR). An approximate 3.1 million facility encounters are added each year. The database also tracks 675,000 commercially insured lives linked with EMR through provider-aligned patient panels, managed care membership files, and a Master Patient Index via a medical record number (i.e., lifetime patient identifier). All EMR, including medication orders and administrative database elements, are available for periods as recent as 30 days from the time of extract.

EMR & Claims Data includes:
- patient demographics
- physician appointments
- clinic visit notes
- clinical laboratory results
- radiology results
- cardiology results
- neurological procedure reports
- anatomic pathology and cytopathology
- operative reports
- operating room procedures
- discharge summaries
- ambulatory care visits (outpatient and emergency department)
- hospital admissions
- inpatient pharmacy
- inpatient medications
- vital signs
- medication orders
- pharmacy and medical claims

Specialty data include, but not limited to, are found in the areas of: 
- Oncology (stage, tumor size, follow-up, etc.) 
- Pulmonology (PFT results, etc.)
- Rheumatology (BMD, T-Scores, etc.)
- Cardiology (Ejection Fraction, PCI, etc.) 
- Geriatrics (MMSE, etc.), and more.

Diagnosis, procedure, and drug data are captured from various sources: The administrative billing data include ambulatory care visits, hospital admissions, operating room procedures, and ancillary services. The full EMR data include clinical laboratory, inpatient pharmacy, and vital signs data. The longitudinal insurance claims data include pharmacy benefit and medical benefit information. Additionally, electronic provider and patient surveys may be customized upon request in order to assess attitudes and preferences.

Database Type
Longitudinal Population Database
- Drug and Diagnosis Data
- - Medical and Pharmacy Insurance Claims
- - - Outpatient and inpatient
- - Electronic Medical Records

(EMRClaims+ accesses administrative insurance claims and links them to an overlapping provider database of EMR)

Database Source
Medical Insurance Claims
EHR/EMR
Frequency of Data Collection
Ongoing
Frequency of Data Update
Ongoing

All EMR, including medication orders and administrative database elements, are available for periods as recent as 30 days from the time of extract; census and death certificates are updated annually.

Years Covered
1988 - Present

Data from Northeastern USA were added to the database in 2016, although the information contained in the Northeast component goes back to 2000.
NOTE: New data are always added depending on the year of the datacut.

Population Type
Outpatient/Non-Institutionalized
Inpatient
Patient Type
Inpatient and Outpatient
Date of Last Update
Ongoing

EMRClaims+ is updated on a monthly basis.
This profile was last updated for the B.R.I.D.G.E. TO DATA site on June 27, 2025.

Field Names
Records
Database Population Size
20 - 50 Million

There are currently more than 20 million electronic records available across 9 states from the Midwest to the Northeast.

Active Population Size
5 - 20 Million

(There are approximately 5.5 million patients active in the database)

Annual Change in Population
~3.1 Million

(~3.1 Million facility encounters are added each year)

Sample Weights - Extrapolation Factors
No
Final Population Size
N/A

(Not applicable as this database continues to collect data)

Field Names
Records
Age of Patients at Data Collection
Yes

Age (years)

Approximate Percentage of Participants <18 years and those >65 years

< 18 years = 10%
> 65 years = 39%

Gender Data
Yes
Percentage of Males/Females

Males = 48%
Females = 52%

Ethnicity / Race Data
Yes
Geographic Location

9 states across Midwest and Northeast USA

Date of Birth Recorded
Yes

This is recorded as mm/dd/yyyy but those data are not released.

Death Recorded
Yes
Availability of death certificate / autopsy information
Yes

Death certificates are received from the state of Michigan Vital Statistics department and matched with patient population to get date of death.

Other Demographic Data
Yes

Data on marital status are captured

Field Names
Records
Physician ID
No
Physician Specialty
Yes
Pharmacy ID
No
Field Names
Records
Diagnosis Data
Yes

Diagnosis data in the administrative and EMR databases are obtained from:
- Clinic visit notes
- Discharge summaries
- Ambulatory care visits
- Hospital admissions
- Medical benefit claims
Additionally, patient-reported outcomes, as well as patient and prescriber preferences and attitudes may be obtained via customized electronic surveys upon request.

Diagnoses Coded
ICD-9-CM
ICD-10-CM
ICD-O-3
Diagnoses: Date Parameters
1988 - Present

NOTE: Data from Northeastern USA were added to the database in 2016, although the information contained in the Northeast component goes back to 2000. Data are updated monthly and recency depends on the time period desired.

Diagnoses: Maximum Number of Codes Allowed
Varies

[Outpatient diagnoses include 1 primary diagnosis and up to 2 additional diagnoses (maximum 3). Up to 35 inpatient diagnoses may be recorded.]

Physical Examination Findings
Yes

Vital signs are captured.
NOTE: Pregnancy could be captured based on a diagnosis code or a CPT pregnancy encounter code.

Birth Defect Data
Yes

Birth defect data are captured via ICD-9-CM and ICD-10-CM coding

Cancer Data
Yes

Cancer data (diagnosis date and incident cases) are captured via ICD-9-CM coding as well as ICD-O-3 for site and histology (cell-type)

Infectious Disease Data
Yes

Infections can be coded with diagnosis codes, but specific organism can be captured in culture results

Environmental Exposures
No
Behavioral Data Elements
Yes

Behavioral data on smoking and alcohol use are routinely recorded but require manual review of patient charts and records

Field Names
Records
Procedure Data
Yes

Procedure data include:
- Clinical laboratory results
- Radiology results
- Cardiology results
- Operating room procedures
- Neurological procedure reports
- Ancillary services
- Anatomic pathology
- Cytopathology

Procedures Coded
CPT-4
Number of Procedures Coded
Varies
Procedure Date Parameters
1988 - Present

NOTE: Data from Northeastern USA were added to the database in 2016, although the information contained in the Northeast component goes back to 2000. Data are updated monthly and recency depends on the time period desired.

Laboratory Information
Yes

Laboratory data include results from:
- Clinical lab tests
- Radiology
- Cardiology
- Neurological procedures
- Anatomic pathology
- Cytopathology.

Note: Some might require manual chart review to determine results.

Field Names
Records
Drug Data
Yes: Prescription & OTC

(Drug data are obtained via pharmacy benefit claims and inpatient pharmacy EMRs; med orders can also be obtained.)

Drug Date Parameters
1988 - Present

NOTE: Data from Northeastern USA were added to the database in 2016, although the information contained in the Northeast component goes back to 2000. Data are updated monthly and recency depends on the time period desired.

Drug Regimen & Route
Yes

As of the addition of EPIC in 2013

Drug Manufacturer
No
Drug Dosage
Yes
Drug Days Supply
Yes
Drug Coding System: Maximum Number
Yes

However, the maximum number of drug codes allowed varies

Drug Coding System: Primary
NDC
Drug Coding System: Other
N/A

(Not applicable)

Drug Generic Name
Yes
Drug Additional Information
Yes

Additional drug information includes:
- Dose information
- Date of prescription claim
- Prescription claim amount
- Refill or not
- Quantity of drug dispensed
- Brand name
- Generic name

Field Names
Records
Biobank Type
N/A
Human Specimen
N/A
Blood Type
N/A
Biomarkers
N/A
Patient ID
N/A
Number of Samples
N/A
Frequency of Sample Collection
N/A
Pre-diagnostic Sample Collection
N/A
Post-treatment Sample Collection
N/A
Method of Sample Collection
N/A
Age at Sample Collection
N/A
Date of Sample Collection
N/A
Reason for Sample Collection
N/A
Method of Sample Storage
N/A
Length of Sample Storage
N/A
Pathology
N/A
DNA Isolation
N/A
RNA Isolation
N/A
Cell Culture
N/A
Genetic Testing
N/A
Access for Research: Specimens
N/A
Access for Research: Genetic Data
N/A
Access for Research: Epidemiologic Data
N/A
Quality Assurance Procedures
N/A
Family History
N/A
Medical History
N/A
Biobank Linkage
N/A
Field Names
Records
Type of Genetic Database
N/A
Source of Genetic Data
N/A
Specimen Genotyped
N/A
Tissue Form
N/A
Genetic Template
N/A
Gene-Drug Response
N/A
Gene-Disease Relationship
N/A
Gene-Health Outcome Relationship
N/A
Gene-Environment Response
N/A
Method of Imputing Genetic Data
N/A
Genetic Variant Identification
N/A
Genetic Data Level
N/A
Genotyping Method
N/A
Method of Genetic Variant Filtering
N/A
Haplotypes
N/A
Haplogroups
N/A
Variable Number of Tandem Repeats (VNTR)
N/A
Single Nucleotide Polymorphisms (SNPs)
N/A
Variant Type
N/A
Variant Class
N/A
Mutation Indicated
N/A
Position
N/A
Amino Acid Change
N/A
Genotype / Polymorphism
N/A
Allele Frequency
N/A
Linkage Disequilibrium (r²)
N/A
Noncarriers Indicated
N/A
Association Statistics
N/A
Genetic Relatedness Pairing
N/A
Data Sharing: Genetic Data
N/A
Access for Research
N/A
Genetic Data Linkage
N/A
Description of Genetic Data Linkage
N/A
Field Names
Records
Cost Data
Yes

Cost data are only available for Midwestern, not for Northeastern US:
- Cost data on medical and pharmacy benefits are obtained via longitudinal insurance claims while cost data on ambulatory care visits
- Hospital admissions
- Operating room procedures
- Ancillary services are obtained via administrative billing data.

Cost Denomination
United States Dollar (USD)

NOTE: For Midwestern USA only

Type of Cost Data
Yes

Information is available on billing and insurance claims for Midwestern USA only, not for Northeastern USA

Description of Surrogate Link
N/A

(Not applicable)

Field Names
Records
Data Validation Against Original Source
No

However, a quality check is conducted at the time of data collection

Access to Medical Records
No

Access to the full EMRs cannot be provided; however, requests for specific information from the EMRs can be granted with IRB approval from HFHS and when a data use agreement has been executed

Linkage to Other Databases
Yes

The EMR data in EMRClaims+ is directly linked to commercial insurance databases such as MarketScan database

Brief Description of Linkage Capabilities

EMRClaims+ also tracks 675,000 commercially insured lives linked with EMR through provider-aligned patient panels, managed care membership files, and a Master Patient Index using a unique medical record number (i.e., patient identifier).

Field Names
Records
Database Contact Data

Julian Casciano
CEO
eMAX Health
1686 S Federal Hwy
Suite 273
Delray Beach, FL 33483
USA
Phone: +1 (914) 304-8128
Fax: +1 (914) 206-4959
Email 1: juliancasciano@emaxhealth.net
Email 2: info@emaxhealth.net

Alternate Contact

1. Zenobia Dotiwala
eMAX Health
1686 S Federal Hwy
Suite 273
Delray Beach, FL 33483
USA
Email: zenobiadotiwala@emaxhealth.net

2. You may also complete the contact form on this page: https://emaxhealth.net/contact-emax-health/

Source of Database Funding
Private

(eMax Health)

Sponsoring Government Agency
N/A

(Not applicable)

Sponsoring Pharmaceutical Manufacturer

N/A

(Not applicable)

Database Usage Restrictions
Private Access

(This is a proprietary database that is available to researchers for purchase)

Charge for Database Usage
Yes

Costs are dependent on the request

Data Media Format
SAS / SPSS

Access database

Number of Publications Using Database
>10
References of Studies Using/Describing Database

1.    Hanania NA, Settipane RA, Khoury S, Shaikh A, Dotiwala Z, Casciano J, Foggs MB. Adding tiotropium or long-acting β2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization. Allergy Asthma Proc. 2023 Nov 13;44(6):413-421.

2. Bender B, Oppenheimer J, George M, Brown R, Patel A, Hill T, Boe A, Mayen Herrera E, Dotiwala Z, Casciano J, Bernstein JA. Assessment of Real-World Escalation to Biologics in US Patients With Asthma. J Allergy Clin Immunol Pract. 2022 Nov;10(11):2941-2948.

3. Mauskop A, Lamerato L, Casciano J, Cohen JM, Thompson SF, Krasenbaum LJ, Dotiwala Z, Tangirala K, McAllister P. Improvements in Patient-reported Migraine Pain Intensity and Composite Migraine Symptoms With Fremanezumab in the Real World. Neurology. 2021 Apr; 96 (15 Supplement): 2114;

4. McAllister P, Casciano J, Cohen J, Thompson S, Krasenbaum L, Dotiwala Z, Tangirala K, Lamerato L. PND98 Real World IMPACT of Fremanezumab Treatment on Headache Frequency and Healthcare Resource Use Among US Patients with Episodic or Chronic Migraine. Value in Health. 2020 Dec 1;23:S640.

5. Diaz-Insa S, Santos S, Benhaddi H, Lee L, Thompson S, Goadsby PJ. PND99 The Humanistic Disease Burden of Episodic and Chronic Migraine in France, Spain and the United Kingdom. Value in Health. 2020 Dec 1;23:S640-1.

6. Dotiwala Z, Casciano J, Davis JR, Fox K, Gopalan G, Rastogi S, Lamerato L, Mathur SK. Effect of clinically significant thresholds of eosinophil elevation on health care resource use in asthma. Annals of Allergy, Asthma & Immunology. 2020 Aug 1;125(2):182-9.

7. Chipps B, Mosnaim G, Mathur SK, Shaikh A, Khoury S, Gopalan G, Palli SR, Lamerato L, Casciano J, Dotiwala Z, Settipane R. Add-on tiotropium versus step-up inhaled corticosteroid plus long-acting beta-2-agonist in real-world patients with asthma. Allergy Asthma Proc. 2020 Jul 1;41(4):248-255.

8. Bellanti JA, Settipane RA. COVID-19, allergic disease and asthma: Extraordinary challenges for the allergist/immunologist. Allergy Asthma Proc. 2020 Jul 1;41(4):229-231. 

9. Casciano J, Krishnan J, Buatti-Small M, Li C, Dotiwala Z. Martin B. Progression to Uncontrolled Severe Asthma: A novel risk equation. J Manag Care Spec Pharm, 2017 Jan; 23(1):44-50.

10. Casciano J, Krishnan J, Dotiwala Z, Li C, Sun S. Clinical and Economic Burden of Elevated Blood Eosinophilia in Patients with and without Uncontrolled asthma. J Manag Care Spec Pharm, 2017 Jan; 23(1):85-91.

    Database Contact
    Database Contact Data

    Julian Casciano
    CEO
    eMAX Health
    1686 S Federal Hwy
    Suite 273
    Delray Beach, FL 33483
    USA
    Phone: +1 (914) 304-8128
    Fax: +1 (914) 206-4959
    Email 1: juliancasciano@emaxhealth.net
    Email 2: info@emaxhealth.net

    Alternate Contact

    1. Zenobia Dotiwala
    eMAX Health
    1686 S Federal Hwy
    Suite 273
    Delray Beach, FL 33483
    USA
    Email: zenobiadotiwala@emaxhealth.net

    2. You may also complete the contact form on this page: https://emaxhealth.net/contact-emax-health/

    References of Studies Using/Describing Database

    1.    Hanania NA, Settipane RA, Khoury S, Shaikh A, Dotiwala Z, Casciano J, Foggs MB. Adding tiotropium or long-acting β2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization. Allergy Asthma Proc. 2023 Nov 13;44(6):413-421.

    2. Bender B, Oppenheimer J, George M, Brown R, Patel A, Hill T, Boe A, Mayen Herrera E, Dotiwala Z, Casciano J, Bernstein JA. Assessment of Real-World Escalation to Biologics in US Patients With Asthma. J Allergy Clin Immunol Pract. 2022 Nov;10(11):2941-2948.

    3. Mauskop A, Lamerato L, Casciano J, Cohen JM, Thompson SF, Krasenbaum LJ, Dotiwala Z, Tangirala K, McAllister P. Improvements in Patient-reported Migraine Pain Intensity and Composite Migraine Symptoms With Fremanezumab in the Real World. Neurology. 2021 Apr; 96 (15 Supplement): 2114;

    4. McAllister P, Casciano J, Cohen J, Thompson S, Krasenbaum L, Dotiwala Z, Tangirala K, Lamerato L. PND98 Real World IMPACT of Fremanezumab Treatment on Headache Frequency and Healthcare Resource Use Among US Patients with Episodic or Chronic Migraine. Value in Health. 2020 Dec 1;23:S640.

    5. Diaz-Insa S, Santos S, Benhaddi H, Lee L, Thompson S, Goadsby PJ. PND99 The Humanistic Disease Burden of Episodic and Chronic Migraine in France, Spain and the United Kingdom. Value in Health. 2020 Dec 1;23:S640-1.

    6. Dotiwala Z, Casciano J, Davis JR, Fox K, Gopalan G, Rastogi S, Lamerato L, Mathur SK. Effect of clinically significant thresholds of eosinophil elevation on health care resource use in asthma. Annals of Allergy, Asthma & Immunology. 2020 Aug 1;125(2):182-9.

    7. Chipps B, Mosnaim G, Mathur SK, Shaikh A, Khoury S, Gopalan G, Palli SR, Lamerato L, Casciano J, Dotiwala Z, Settipane R. Add-on tiotropium versus step-up inhaled corticosteroid plus long-acting beta-2-agonist in real-world patients with asthma. Allergy Asthma Proc. 2020 Jul 1;41(4):248-255.

    8. Bellanti JA, Settipane RA. COVID-19, allergic disease and asthma: Extraordinary challenges for the allergist/immunologist. Allergy Asthma Proc. 2020 Jul 1;41(4):229-231. 

    9. Casciano J, Krishnan J, Buatti-Small M, Li C, Dotiwala Z. Martin B. Progression to Uncontrolled Severe Asthma: A novel risk equation. J Manag Care Spec Pharm, 2017 Jan; 23(1):44-50.

    10. Casciano J, Krishnan J, Dotiwala Z, Li C, Sun S. Clinical and Economic Burden of Elevated Blood Eosinophilia in Patients with and without Uncontrolled asthma. J Manag Care Spec Pharm, 2017 Jan; 23(1):85-91.